EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSHBUG00000008539
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSHBUG00000013734
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSHBUG00000022339
Gene Symbol: NR3C1
2 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSHBUG00000008760
Gene Symbol: NR3C2
2 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSHBUG00000021836
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSHBUG00000016074
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSHBUG00000001833
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSHBUG00000013219
Gene Symbol: OXTR
3 Cross references
191 Possible Orthologues:

Parathyroid Hormone/parathyroid Hormone-Related Peptide Receptor-Like

Ensembl ID : ENSHBUG00000008845
Gene Symbol: LOC102311921
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSHBUG00000004373
Gene Symbol: PPARA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSHBUG00000022834
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSHBUG00000009776
Gene Symbol: PPARG
4 Cross references
386 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).